Nilotinib Teva (Nilotinib)

Nilotinib selectively blocks the BCR‑ABL tyrosine kinase, preventing the enzyme from activating downstream pathways that promote cell proliferation and survival. This inhibition leads to reduced growth of leukemic cells and can induce remission in CML.

The prescribed dose of Nilotinib Teva is determined by the treating physician based on the patient’s clinical condition, disease phase, and other individual factors. Dosing instructions are provided on the prescription label.

The safety of Nilotinib in pregnancy or while breastfeeding has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib belongs to the tyrosine kinase inhibitor class, similar to imatinib and dasatinib. Compared with first‑generation inhibitors, Nilotinib offers higher potency against BCR‑ABL and may be used when resistance or intolerance to earlier agents occurs.

Nilotinib Teva tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Do not store in a refrigerator or freezer.

Nilotinib Teva is taken orally, usually as whole tablets with a moderate‑fat meal. The exact administration schedule, including timing relative to meals, is defined by the prescribing clinician.

Serious risks include cardiovascular events such as arterial occlusion, severe liver toxicity, pancreatitis, and QT interval prolongation, which can lead to dangerous heart rhythm disturbances. Patients should be monitored regularly for these conditions.

Patients with known hypersensitivity to Nilotinib or any of its excipients should avoid the drug. It is also contraindicated in individuals with uncontrolled cardiac disease, severe hepatic impairment, or those taking prohibited strong CYP3A4 inhibitors.